胰腺神经内分泌瘤研究热点与趋势：2015~2024年文献计量分析
Research Trends and Hotspots on Pancreatic Neuroendocrine Tumor: A Bibliometric Analysis from 2015 to 2024
DOI: 10.12677/acm.2026.163969, PDF,   
作者: 袁 瑞, 邓 亮*：重庆医科大学附属第一医院消化内科，重庆；张 可：重庆医科大学附属第一医院放射科，重庆
关键词: 胰腺肿瘤；胰腺神经内分泌瘤；文献计量分析；Pancreatic Neoplasms； Pancreatic Neuroendocrine Tumor； Bibliometric Analysis
摘要: 背景：胰腺神经内分泌瘤是一种临床罕见且具有高度异质性的肿瘤，其发病率正逐年增加。本研究旨在通过文献计量学方法，系统地分析胰腺神经内分泌瘤领域内的研究现状、热点与趋势，为临床工作者和研究者提供参考。方法：本研究基于Web of Science核心合集数据库，借助VOSviewer、CiteSpace软件对胰腺神经内分泌瘤研究的发文趋势、发文期刊、国际合作情况、机构发文情况及研究热点进行可视化分析。结果：共检索到相关文献2527篇，其中中国是发文数量最多的国家(986篇，39.02%)，阿姆斯特丹大学是发文数量最多的研究机构(110篇，4.35%)，深度学习与人工智能是目前突现强度最高的关键词，人工智能与免疫浸润已成为该领域关键研究领域。结论：本研究发现深度学习与人工智能是最突出且快速发展的研究主题，免疫浸润也成为重要研究方向。未来胰腺神经内分泌瘤领域的研究热点或许正从肿瘤生物学和治疗策略转向诊断与预后研究。
Abstract: Background: Pancreatic neuroendocrine tumors (pNETs) are rare but clinically heterogeneous neoplasms with increasing incidence. We aimed to conduct a comprehensive bibliometric analysis of publications related to pNET in order to elucidate the current research trends and forecast future hotspots in this field. Methods: Articles correlated with pNET published from 2015 to 2024 were searched from the Web of Science Core Collection. Then, the searched data were analyzed using VOSviewer, CiteSpace, and R language. Finally, burst detection, clustering analysis and thematic map analysis were performed to identify shifts in the research frontier of pNET. Results: Since 2015, a total of 2527 articles on pNET have been published. China was the leading contributor among all countries (986, 39.02%), while the University of Amsterdam ranked first (110, 4.35%) among institutions. Deep learning and artificial intelligence were citation key words with the strongest ongoing bursts. Key research areas include artificial intelligence and immune infiltration. Conclusions: The study identifies deep learning and artificial intelligence as the most prominent and rapidly evolving research themes, with immune infiltration also emerging as a key area of interest. These findings indicate a shift in research hotspots from tumor biology and treatment strategies to diagnostics and prognosis.
文章引用：袁瑞, 张可, 邓亮. 胰腺神经内分泌瘤研究热点与趋势：2015~2024年文献计量分析[J]. 临床医学进展, 2026, 16(3): 1831-1844. https://doi.org/10.12677/acm.2026.163969

参考文献

[1] Kamisawa, T., Wood, L.D., Itoi, T. and Takaori, K. (2016) Pancreatic Cancer. The Lancet (London, England), 388, 73-85. [Google Scholar] [CrossRef] [PubMed]
[2] Roth, G.A., Abate, D., Abate, K.H., Abay, S.M., Abbafati, C., Abbasi, N., et al. (2018) Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet, 392, 1736-1788. [Google Scholar] [CrossRef] [PubMed]
[3] Rindi, G., Mete, O., Uccella, S., Basturk, O., La Rosa, S., Brosens, L.A.A., et al. (2022) Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology, 33, 115-154. [Google Scholar] [CrossRef] [PubMed]
[4] Hallet, J., Law, C.H.L., Cukier, M., Saskin, R., Liu, N. and Singh, S. (2014) Exploring the Rising Incidence of Neuroendocrine Tumors: A Population‐Based Analysis of Epidemiology, Metastatic Presentation, and Outcomes. Cancer, 121, 589-597. [Google Scholar] [CrossRef] [PubMed]
[5] Yadav, S., Sharma, P. and Zakalik, D. (2018) Comparison of Demographics, Tumor Characteristics, and Survival between Pancreatic Adenocarcinomas and Pancreatic Neuroendocrine Tumors: A Population-Based Study. American Journal of Clinical Oncology, 41, 485-491. [Google Scholar] [CrossRef] [PubMed]
[6] O’Grady, H.L. and Conlon, K.C. (2008) Pancreatic Neuroendocrine Tumours. European Journal of Surgical Oncology (EJSO), 34, 324-332. [Google Scholar] [CrossRef] [PubMed]
[7] Kimura, T., Miyamoto, H., Fukuya, A., Kitamura, S., Okamoto, K., Kimura, M., et al. (2016) Neuroendocrine Carcinoma of the Pancreas with Similar Genetic Alterations to Invasive Ductal Adenocarcinoma. Clinical Journal of Gastroenterology, 9, 261-265. [Google Scholar] [CrossRef] [PubMed]
[8] Raman, S.P., Hruban, R.H., Cameron, J.L., Wolfgang, C.L. and Fishman, E.K. (2012) Pancreatic Imaging Mimics: Part 2, Pancreatic Neuroendocrine Tumors and Their Mimics. American Journal of Roentgenology, 199, 309-318. [Google Scholar] [CrossRef] [PubMed]
[9] Hicks, D., Wouters, P., Waltman, L., de Rijcke, S. and Rafols, I. (2015) Bibliometrics: The Leiden Manifesto for Research Metrics. Nature, 520, 429-431. [Google Scholar] [CrossRef] [PubMed]
[10] Crinò, S.F., Napoleon, B., Facciorusso, A., Lakhtakia, S., Borbath, I., Caillol, F., et al. (2023) Endoscopic Ultrasound-Guided Radiofrequency Ablation versus Surgical Resection for Treatment of Pancreatic Insulinoma. Clinical Gastroenterology and Hepatology, 21, 2834-2843.e2. [Google Scholar] [CrossRef] [PubMed]
[11] Santucci, N., Gaujoux, S., Binquet, C., Reichling, C., Lifante, J., Carnaille, B., et al. (2021) Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: An AFCE (Association Francophone De Chirurgie Endocrinienne) and GTE (Groupe D’étude Des Tumeurs Endocrines) Study. World Journal of Surgery, 45, 1794-1802. [Google Scholar] [CrossRef] [PubMed]
[12] van Beek, D., Nell, S., Pieterman, C.R.C., de Herder, W.W., van de Ven, A.C., Dekkers, O.M., et al. (2019) Prognostic Factors and Survival in MEN1 Patients with Gastrinomas: Results from the DutchMEN Study Group (DMSG). Journal of Surgical Oncology, 120, 966-975. [Google Scholar] [CrossRef] [PubMed]
[13] Faggiano, A., Modica, R., Lo Calzo, F., Camera, L., Napolitano, V., Altieri, B., et al. (2019) Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters. The Journal of Clinical Endocrinology & Metabolism, 105, 78-84. [Google Scholar] [CrossRef] [PubMed]
[14] Jin, X., Spampatti, M.P., Spitzweg, C. and Auernhammer, C.J. (2018) Supportive Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Often Forgotten but Important. Reviews in Endocrine and Metabolic Disorders, 19, 145-158. [Google Scholar] [CrossRef] [PubMed]
[15] Brugel, M., Walter, T., Goichot, B., Smith, D., Lepage, C., Cao, C.D., et al. (2021) Efficacy of Treatments for Vipoma: A GTE Multicentric Series. Pancreatology, 21, 1531-1539. [Google Scholar] [CrossRef] [PubMed]
[16] Von Hoff, D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M., et al. (2013) Increased Survival in Pancreatic Cancer with Nab-Paclitaxel Plus Gemcitabine. New England Journal of Medicine, 369, 1691-1703. [Google Scholar] [CrossRef] [PubMed]
[17] Lindeman, P. and Holmquist, J. (1987) Mastoid Volume and Eustachian Tube Function in Ears with Cholesteatoma. The American Journal of Otology, 8, 5-7.
[18] Khan, M.S., Kirkwood, A., Tsigani, T., Garcia-Hernandez, J., Hartley, J.A., Caplin, M.E., et al. (2013) Circulating Tumor Cells as Prognostic Markers in Neuroendocrine Tumors. Journal of Clinical Oncology, 31, 365-372. [Google Scholar] [CrossRef] [PubMed]
[19] Takahashi, D., Kojima, M., Suzuki, T., Sugimoto, M., Kobayashi, S., Takahashi, S., et al. (2018) Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification. Scientific Reports, 8, Article No. 13166. [Google Scholar] [CrossRef] [PubMed]
[20] Hussen, B.M., Hidayat, H.J., Salihi, A., Sabir, D.K., Taheri, M. and Ghafouri-Fard, S. (2021) MicroRNA: A Signature for Cancer Progression. Biomedicine & Pharmacotherapy, 138, Article ID: 111528. [Google Scholar] [CrossRef] [PubMed]
[21] Thorns, C., Schurmann, C., Gebauer, N., et al (2014) Global microRNA Profiling of Pancreatic Neuroendocrine Neoplasias. Anticancer Research, 34, 2249-2254.
[22] Luo, Y., Chen, X., Chen, J., Song, C., Shen, J., Xiao, H., et al. (2019) Preoperative Prediction of Pancreatic Neuroendocrine Neoplasms Grading Based on Enhanced Computed Tomography Imaging: Validation of Deep Learning with a Convolutional Neural Network. Neuroendocrinology, 110, 338-350. [Google Scholar] [CrossRef] [PubMed]
[23] Si, K., Xue, Y., Yu, X., Zhu, X., Li, Q., Gong, W., et al. (2021) Fully End-to-End Deep-Learning-Based Diagnosis of Pancreatic Tumors. Theranostics, 11, 1982-1990. [Google Scholar] [CrossRef] [PubMed]
[24] Murakami, M., Fujimori, N., Nakata, K., Nakamura, M., Hashimoto, S., Kurahara, H., et al. (2023) Machine Learning-Based Model for Prediction and Feature Analysis of Recurrence in Pancreatic Neuroendocrine Tumors G1/G2. Journal of Gastroenterology, 58, 586-597. [Google Scholar] [CrossRef] [PubMed]
[25] Greenberg, J.A., Shah, Y., Ivanov, N.A., Marshall, T., Kulm, S., Williams, J., et al. (2024) Developing a Predictive Model for Metastatic Potential in Pancreatic Neuroendocrine Tumor. The Journal of Clinical Endocrinology & Metabolism, 110, 263-274. [Google Scholar] [CrossRef] [PubMed]
[26] Ye, J., Fang, P., Peng, Z., Huang, X., Xie, J. and Yin, X. (2023) A Radiomics-Based Interpretable Model to Predict the Pathological Grade of Pancreatic Neuroendocrine Tumors. European Radiology, 34, 1994-2005. [Google Scholar] [CrossRef] [PubMed]
[27] Gu, W., Chen, Y., Zhu, H., Chen, H., Yang, Z., Mo, S., et al. (2023) Development and Validation of CT-Based Radiomics Deep Learning Signatures to Predict Lymph Node Metastasis in Non-Functional Pancreatic Neuroendocrine Tumors: A Multicohort Study. eClinicalMedicine, 65, Article ID: 102269. [Google Scholar] [CrossRef] [PubMed]
[28] Ma, M., Gu, W., Liang, Y., Han, X., Zhang, M., Xu, M., et al. (2024) A Novel Model for Predicting Postoperative Liver Metastasis in R0 Resected Pancreatic Neuroendocrine Tumors: Integrating Computational Pathology and Deep Learning-Radiomics. Journal of Translational Medicine, 22, Article No. 768. [Google Scholar] [CrossRef] [PubMed]
[29] Wang, X., Qiu, J., Tan, C., Chen, Y., Tan, Q., Ren, S., et al. (2022) Development and Validation of a Novel Radiomics-Based Nomogram with Machine Learning to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors. Frontiers in Oncology, 12, Article ID: 843376. [Google Scholar] [CrossRef] [PubMed]
[30] Teulé, A. and Casanovas, O. (2012) Relevance of Angiogenesis in Neuroendocrine Tumors. Targeted Oncology, 7, 93-98. [Google Scholar] [CrossRef] [PubMed]
[31] Jiménez-Fonseca, P., Martín, M.N., Carmona-Bayonas, A., Calvo, A., Fernández-Mateos, J., Redrado, M., et al. (2018) Biomarkers and Polymorphisms in Pancreatic Neuroendocrine Tumors Treated with Sunitinib. Oncotarget, 9, 36894-36905. [Google Scholar] [CrossRef] [PubMed]
[32] Berković, M.C., Jokić, M., Marout, J., Radošević, S., Zjačić-Rotkvić, V. and Kapitanović, S. (2007) IL-6-174 C/G Polymorphism in the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs). Experimental and Molecular Pathology, 83, 474-479. [Google Scholar] [CrossRef] [PubMed]
[33] Hussain, F., Wang, J., Ahmed, R., Guest, S.K., Lam, E.W., Stamp, G., et al. (2010) The Expression of IL-8 and IL-8 Receptors in Pancreatic Adenocarcinomas and Pancreatic Neuroendocrine Tumours. Cytokine, 49, 134-140. [Google Scholar] [CrossRef] [PubMed]
[34] Zurita, A.J., Khajavi, M., Wu, H., Tye, L., Huang, X., Kulke, M.H., et al. (2015) Circulating Cytokines and Monocyte Subpopulations as Biomarkers of Outcome and Biological Activity in Sunitinib-Treated Patients with Advanced Neuroendocrine Tumours. British Journal of Cancer, 112, 1199-1205. [Google Scholar] [CrossRef] [PubMed]
[35] Karakaxas, D., Sioziou, A., Aravantinos, G., Coker, A., Papanikolaou, I.S., Liakakos, T., et al. (2016) Genetic Polymorphisms of Interleukin 1β Gene and Sporadic Pancreatic Neuroendocrine Tumors Susceptibility. World Journal of Gastrointestinal Oncology, 8, 520-525. [Google Scholar] [CrossRef] [PubMed]

为你推荐